Relmada Therapeutics, Inc. RLMD Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s total equity?
- Relmada Therapeutics, Inc. (RLMD) reported total equity of $218.73M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s total equity changed year-over-year?
- Relmada Therapeutics, Inc.'s total equity increased by 874.7% year-over-year, from $22.44M to $218.73M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s total equity has grown at a -3.9% compound annual growth rate (CAGR), from $105.58M to $86.51M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.